Glenmark Settles Lunesta Patent Spat With Sepracor

Law360, New York (August 9, 2010, 1:55 PM EDT) -- Glenmark Pharmaceuticals Ltd. has reached a settlement with Sepracor Inc., putting to rest a patent infringement fight launched by Sepracor over the insomnia treatment sold under the brand name Lunesta.

In a statement announcing the agreement, Glenmark said the settlement will allow the company to begin marketing generic eszopiclone tablets either on Nov. 30, 2013 — two and a half months before Sepracor's U.S. Patent Number 6,444,673 expires — or on May 30, 2014, if Sepracor obtains pediatric exclusivity for Lunesta.

The settlement and licensing agreement...
To view the full article, register now.